Moleculin Biotech Inc. (NASDAQ: MBRX)
$4.39
+0.1400 ( +3.29% ) 1.0K
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Market Data
Open
$4.39
Previous close
$4.25
Volume
1.0K
Market cap
$9.62M
Day range
$4.12 - $4.30
52 week range
$3.22 - $15.75
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 16 | Dec 11, 2023 |
8-k | 8K-related | 17 | Nov 20, 2023 |
8-k | 8K-related | 16 | Nov 13, 2023 |
8-k | 8K-related | 16 | Nov 13, 2023 |
10-q | Quarterly Reports | 52 | Nov 13, 2023 |
8-k | 8K-related | 41 | Nov 13, 2023 |
8-k | 8K-related | 16 | Nov 07, 2023 |
8-k | 8K-related | 16 | Nov 06, 2023 |
8-k | 8K-related | 14 | Nov 03, 2023 |
8-k | 8K-related | 17 | Oct 17, 2023 |